Editorial: comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting anti‐viral agents in chronic hepatitis C – authors’ reply

Abstract

1. Hepatitis C. guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932‐954. 2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153‐194. 3. Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702‐726. 4. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76‐139. 5. Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician s guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016;63:634‐ 643. 6. Liu CH, Yu ML, Peng CY, et al. Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐ acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther. 2018;48:1290‐1300. 7. Siederdissen C, Maasoumy B, Marra F, et al. Drug‐drug interactions with novel all oral interferon‐free antiviral agents in a large real‐world cohort. Clin Infect Dis. 2016;62:561‐567. 8. AASLD‐IDSA.Unique populations. Renal impairment. Recommendations for testing, managing, and treating hepatitis C. Accessed October 7, 2018. 9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018.